Plasminogen activation in human leukemia and in normal hematopoietic cells

APMIS

Volumn 107, Issue 1, 1999, Pages 144-149

  Mustjoki, Satu ^a   Alitalo, Riitta ^a,b   Stephens, Ross W ^c   Vaheri, Antti ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c FINSEN LABORATORY   (Denmark)

Author keywords

Bleeding; Blood cells; Leukemia; Plasminogen; Review; Urokinase

Indexed keywords

PLASMINOGEN; UROKINASE;

BLEEDING TENDENCY; CELL INFILTRATION; CELL INVASION; COMORBIDITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; PATHOGENESIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; THROMBOCYTOPENIA;

EID: 0033047130     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01537.x     Document Type: Review

References (59)

1. 1. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: From genetics to treatment. Blood 1994;83:10-25.
2. 2. Casini T, Grignani F, Pelicci GP. Genetics of APL and the molecular basis of retinoic acid treatment. Int J Cancer 1997;70:473-4.
3. 3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. The French-American-British (FAB) co-operative Group. Br J Haematol 1976;33:451-8.
4. 4. Warrell RPJ. Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia. Int J Cancer 1997;70:496-7.
5. 5. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 79:1704-9.
6. 6. Dombret H, Scrobohaci ML, Ghorra P, et al. Coagulation disorders associated with acute promyelocytic leukemia: Corrective effect of all-trans retinoic acid treatment. Leukemia 1993;7:2-9.
7. 7. Sier CFM, Stephens RW, Bizik J, et al. The level of urokinase type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9.
8. 8. Pedersen N, Schmitt M, Rønne E, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993;92:2160-7.
9. 9. Stephens RW, Pedersen A, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1868-76.
10. 10. Mizukami I, Faulkner N, Gyetko M, Sitrin R, Todd III R. Enzyme-linked immunosorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995;86:203-11.
11. 11. Rønne E, Pappot H, Grøndahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;89:576-81.
12. 12. Pappot H, Høyer-Hansen G, Rønne E, et al. Elevated levels of receptor for urokinase plasminogen activator in patients with non-small cell lung cancer. Eur J Cancer 1997;33:867-72.
13. 13. Stephens R, Alitalo R, Tapiovaara H, Vaheri A. Production of an active urokinase by leukemia cells: A novel distinction from cell lines of solid tumors. Leukemia Res 1988;12:419-22.
14. 14. Tapiovaara H, Vaheri A, Alitalo R, Pheng-Siew S, Woodrow G, Stephens RW. Enhanced activation of pro-urokinase by human RC2A leukemia cells. Semin Thromb Hemostas 1991;17:251-61.
15. 15. Tapiovaara H, Stephens RW, Vaheri A. Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro. Int J Cancer 1993;53:499-505.
16. 16. Reiter I, Spertini O, Kruithof E. Plasminogen activators play an essential role in extracellular-matrix invasion by lymphoblastic T cells. lnt J Cancer 1997;70:461-6.
17. 17. Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood 1994;83:1883-91.
18. 18. Mustjoki S, Tapiovaara H, Sirén V, Vaheri A. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells. Leukemia 1998;12:164-74.
19. 19. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RPJ. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Int Med 1992;117:292-6.
20. 20. Kidron M, Nachshon I, Mayer M, Fibach E. Plasminogen activator activity in differentiating leukemia cells. FEBS Lett 1984;177:66-70.
21. 21. McWilliam NA, Robbie LA, Barelle CJ, et al. Evidence for an active fibrinolytic system in normal human bone marrow. Br J Haematol 1996;93:170-6.
22. 22. Plesner T, Rafkier E, Wittrup M, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994;102:835-41.
23. 23. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 1997;15:398-408.
24. 24. Wilson EL, Jacobs P, Francis GE, Oliver L, Burger P, Dowdle EB. Secretion of plasminogen activators by normal bone marrow cells and leukaemic myeloid cells. Fibrinolysis 1992;6:77-9.
25. 25. Jardi M, Ingles-Esteve J, Burgal M, et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thromb Haemost 1996;76:1009-19.
26. 26. Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thromb Haemost 1987;58:936-42.
27. 27. Nykjaer A, Møller B, Todd III RF, et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 1994;152:505-16.
28. 28. Mabilat-Pragnon C, Janin A, Thomaidis A, Legrand Y, Soria C, Lu H. Urokinase localization and activity in isolated eosinophils. Thromb Res 1997;88:373-9.
29. 29. Wilson L, G.E. F. Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human hemopoietic cells. J Exp Med 1987;165:1609-23.
30. 30. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preisner KT. The urokinase receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 1997;77:540-7.
31. 31. Jeanneau C, Sultan Y. Tissue plasminogen activator in human megakaryocytes and platelets: immunocytochemical localization, immunoblotting and zymographic analysis. Thromb Haemost 1988;59:529-34.
32. 32. Brisson-Jeanneau C, Nelles L, Rouer E, Sultan Y, Benarous R. Tissue-plasminogen activator RNA detected in megakaryocytes by in situ hybridization and biotinylated probe. Histochemistry 1990;95:23-6.
33. 33. Alessi MC, Chomiki N, Berthier R, Schweitzer A, Fossat C, Juhan-Vague I. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. Thromb Haemost 1994;72:931-6.
34. 34. Bianchi E, Ferrero E, Fazioli F, et al. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest 1996;98:1133-41.
35. 35. Gyetko MR, Todd RFI, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994;93:1380-7.
36. 36. Gyetko MR, Chen G-H, McDonald RA, et al. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J Clin Invest 1996;97:1818-26.
37. 37. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997;16:7279-86.
38. 38. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997;18:415-7.
39. 39. Stephens RW, Tapiovaara H, Alitalo R, et al. Cell-surface plasminogen activation and leukemia. Fibrinolysis 1992;6:35-9.
40. 40. Tapiovaara H, Alitalo R, Vaheri A. Plasminogen activation on tumor cell surface and its involvement in human leukemia. Adv Cancer Res 1996;69:101-33.
41. 41. Wilson EL, Jacobs P, Dowdle EB. The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood 1983;61:568-74.
42. 42. Wada H, Kumeda Y, Ogasawara Z, et al. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol 1993;42:166-70.
43. 43. Tapiovaara H, Alitalo R, Stephens RW, Myöhänen H, Ruutu T, Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood 1993;82:914-9.
44. 44. Castagnari B, Moretti S, Latorraca A, et al. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (uPA-R) in acute myeloid leukemia cells. Boll Soc Ital Biol Sperim 1995;71:141-7.
45. 45. Scherrer A, Kruithof EKO, Grob J-P. Plasminogen activator inhibitor-2 in patients with monocytic leukemia. Leukemia 1991;5:479-86.
46. 46. Garcia Frade LJ, Sureda A, Torrado MC, Garcia Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. Acta Haematol 1992;88:7-10.
47. 47. Akenami F, Sirén V, Koskiniemi M, Siimes MA, Teräväinen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996;49:577-80.
48. 48. McWilliam N, Robbie L, Booth N, Bennet B. Plasminogen activator in acute myeloid leukaemic marrows: uPA in contrast to t-PA in normal marrow. Br J Haematol 1998;101:626-31.
49. 49. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992;79:543-53.
50. 50. Dombret H, Scrobohaci M-L, Daniel M-T, et al. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995;9:19-24.
51. 51. Fukao H, Ueshima S, Okada K, Yamamoto K, Matsuo T, Matsuo O. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation. Thromb Res 1992;68:57-65.
52. 52. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991;77:1949-57.
53. 53. Lopez-Pedrera C, Jardi M, del Mar Malagon M, et al. Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients. Thromb Haemost 1997;77:62-70.
54. 54. Bennett B, Croll AM, Robbie LA, Herriot R. Tumour cell u-PA as a cause of fibrinolytic bleeding in metastatic disease. Br J Haematol 1997;99:570-4.
55. 55. Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:153-63.
56. 56. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997;78:285-96.
57. 57. Rønne E, Høyer-Hansen G, Brünner N. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono-and polyclonal antibodies. Breast Cancer Res Treat 1995;33:199-207.
58. 58. Ganesh S, Sier CF, Griffioen G. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-71.
59. 59. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy Thromb Haemost 1999 (in press).